Literature DB >> 29180446

Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation.

Li Zhou1, Viktor Todorovic2, Steve Kakavas2, Bernhard Sielaff3, Limary Medina3, Leyu Wang3, Ramkrishna Sadhukhan3, Henning Stockmann2, Paul L Richardson2, Enrico DiGiammarino2, Chaohong Sun2, Victoria Scott2.   

Abstract

IL-36 cytokines signal through the IL-36 receptor (IL-36R) and a shared subunit, IL-1RAcP (IL-1 receptor accessory protein). The activation mechanism for the IL-36 pathway is proposed to be similar to that of IL-1 in that an IL-36R agonist (IL-36α, IL-36β, or IL-36γ) forms a binary complex with IL-36R, which then recruits IL-1RAcP. Recent studies have shown that IL-36R interacts with IL-1RAcP even in the absence of an agonist. To elucidate the IL-36 activation mechanism, we considered all possible binding events for IL-36 ligands/receptors and examined these events in direct binding assays. Our results indicated that the agonists bind the IL-36R extracellular domain with micromolar affinity but do not detectably bind IL-1RAcP. Using surface plasmon resonance (SPR), we found that IL-1RAcP also does not bind IL-36R when no agonist is present. In the presence of IL-36α, however, IL-1RAcP bound IL-36R strongly. These results suggested that the main pathway to the IL-36R·IL-36α·IL-1RAcP ternary complex is through the IL-36R·IL-36α binary complex, which recruits IL-1RAcP. We could not measure the binding affinity of IL-36R to IL-1RAcP directly, so we engineered a fragment crystallizable-linked construct to induce IL-36R·IL-1RAcP heterodimerization and predicted the binding affinity during a complete thermodynamic cycle to be 74 μm The SPR analysis also indicated that the IL-36R antagonist IL-36Ra binds IL-36R with higher affinity and a much slower off rate than the IL-36R agonists, shedding light on IL-36 pathway inhibition. Our results reveal the landscape of IL-36 ligand and receptor interactions, improving our understanding of IL-36 pathway activation and inhibition.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  IL-1Rrp2; IL-36R; immunology; kinetics; protein–protein interaction; signaling; surface plasmon resonance (SPR)

Mesh:

Substances:

Year:  2017        PMID: 29180446      PMCID: PMC5767850          DOI: 10.1074/jbc.M117.805739

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

Review 2.  Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions.

Authors:  Cem Gabay; Jennifer E Towne
Journal:  J Leukoc Biol       Date:  2015-02-11       Impact factor: 4.962

3.  Inflammation: IL-36 has proinflammatory effects in skin but not in joints.

Authors:  Damien Dietrich; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

4.  IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions.

Authors:  Angelo Massimiliano D'Erme; Dagmar Wilsmann-Theis; Julia Wagenpfeil; Michael Hölzel; Sandra Ferring-Schmitt; Sonja Sternberg; Miriam Wittmann; Bettina Peters; Andreas Bosio; Thomas Bieber; Joerg Wenzel
Journal:  J Invest Dermatol       Date:  2014-12-19       Impact factor: 8.551

5.  Cell-Surface Receptor-Ligand Interaction Analysis with Homogeneous Time-Resolved FRET and Metabolic Glycan Engineering: Application to Transmembrane and GPI-Anchored Receptors.

Authors:  Henning Stockmann; Viktor Todorovic; Paul L Richardson; Violeta Marin; Victoria Scott; Clare Gerstein; Marc Lake; Leyu Wang; Ramkrishna Sadhukhan; Anil Vasudevan
Journal:  J Am Chem Soc       Date:  2017-11-09       Impact factor: 15.419

6.  Structural insights into the assembly and activation of IL-1β with its receptors.

Authors:  Dongli Wang; Senyan Zhang; Liang Li; Xi Liu; Kunrong Mei; Xinquan Wang
Journal:  Nat Immunol       Date:  2010-08-29       Impact factor: 25.606

Review 7.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

8.  IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin.

Authors:  Alexander M Foster; Jaymie Baliwag; Cynthia S Chen; Andrew M Guzman; Stefan W Stoll; Johann E Gudjonsson; Nicole L Ward; Andrew Johnston
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

9.  Biological activity and receptor binding of human prointerleukin-1 beta and subpeptides.

Authors:  S A Jobling; P E Auron; G Gurka; A C Webb; B McDonald; L J Rosenwasser; L Gehrke
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

10.  Transforming binding affinities from three dimensions to two with application to cadherin clustering.

Authors:  Yinghao Wu; Jeremie Vendome; Lawrence Shapiro; Avinoam Ben-Shaul; Barry Honig
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

View more
  12 in total

1.  IL-36γ Protects against Severe Influenza Infection by Promoting Lung Alveolar Macrophage Survival and Limiting Viral Replication.

Authors:  Alexander N Wein; Paul R Dunbar; Sean R McMaster; Zheng-Rong Tiger Li; Timothy L Denning; Jacob E Kohlmeier
Journal:  J Immunol       Date:  2018-05-30       Impact factor: 5.422

2.  LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma.

Authors:  Chamutal Gur; Shuang-Yin Wang; Fadi Sheban; Mor Zada; Baoguo Li; Fadi Kharouf; Hagit Peleg; Suhail Aamar; Adam Yalin; Daniel Kirschenbaum; Yolanda Braun-Moscovici; Diego Adhemar Jaitin; Tomer Meir-Salame; Efrat Hagai; Bjørt K Kragesteen; Batia Avni; Sigal Grisariu; Chamutal Bornstein; Shir Shlomi-Loubaton; Eyal David; Rony Shreberk-Hassidim; Vered Molho-Pessach; Dalit Amar; Tomer Tzur; Rottem Kuint; Moshe Gross; Oren Barboy; Adi Moshe; Liat Fellus-Alyagor; Dana Hirsch; Yoseph Addadi; Shlomit Erenfeld; Moshe Biton; Tehila Tzemach; Anat Elazary; Yaakov Naparstek; Reut Tzemach; Assaf Weiner; Amir Giladi; Alexandra Balbir-Gurman; Ido Amit
Journal:  Cell       Date:  2022-04-04       Impact factor: 66.850

Review 3.  Interleukin-36: Structure, Signaling and Function.

Authors:  Li Zhou; Viktor Todorovic
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 5.  How to Get Started with Single Cell RNA Sequencing Data Analysis.

Authors:  Michael S Balzer; Ziyuan Ma; Jianfu Zhou; Amin Abedini; Katalin Susztak
Journal:  J Am Soc Nephrol       Date:  2021-03-15       Impact factor: 14.978

6.  Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Authors:  Viktor Todorović; Zhi Su; C Brent Putman; Stevan J Kakavas; Katherine M Salte; Heath A McDonald; Joseph B Wetter; Stephanie E Paulsboe; Qi Sun; Clare E Gerstein; Limary Medina; Bernhard Sielaff; Ramkrishna Sadhukhan; Henning Stockmann; Paul L Richardson; Wei Qiu; Maria A Argiriadi; Rodger F Henry; J Martin Herold; J Brad Shotwell; Steve P McGaraughty; Prisca Honore; Sujatha M Gopalakrishnan; Chaohong C Sun; Victoria E Scott
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

Review 7.  IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential.

Authors:  Marie-Astrid Boutet; Alessandra Nerviani; Costantino Pitzalis
Journal:  Int J Mol Sci       Date:  2019-03-13       Impact factor: 5.923

Review 8.  Interleukin-36 Cytokines in Infectious and Non-Infectious Lung Diseases.

Authors:  Hernán F Peñaloza; Rick van der Geest; Joel A Ybe; Theodore J Standiford; Janet S Lee
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

9.  Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis.

Authors:  Marie-Astrid Boutet; Alessandra Nerviani; Gloria Lliso-Ribera; Davide Lucchesi; Edoardo Prediletto; Giulia Maria Ghirardi; Katriona Goldmann; Myles Lewis; Costantino Pitzalis
Journal:  Rheumatology (Oxford)       Date:  2020-04-01       Impact factor: 7.580

10.  Deficiency of Interleukin-36 Receptor Protected Cardiomyocytes from Ischemia-Reperfusion Injury in Cardiopulmonary Bypass.

Authors:  Cheng Luo; Xiaoyong Xie; Xu Feng; Binfeng Lei; Chen Fang; Yugui Li; Xiongwei Cai; Guoxing Ling; Baoshi Zheng
Journal:  Med Sci Monit       Date:  2020-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.